These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 9427330)
1. Effects of bromocriptine on human subjects depend on working memory capacity. Kimberg DY; D'Esposito M; Farah MJ Neuroreport; 1997 Nov; 8(16):3581-5. PubMed ID: 9427330 [TBL] [Abstract][Full Text] [Related]
2. Individual capacity differences predict working memory performance and prefrontal activity following dopamine receptor stimulation. Gibbs SE; D'Esposito M Cogn Affect Behav Neurosci; 2005 Jun; 5(2):212-21. PubMed ID: 16180627 [TBL] [Abstract][Full Text] [Related]
3. Improved short-term spatial memory but impaired reversal learning following the dopamine D(2) agonist bromocriptine in human volunteers. Mehta MA; Swainson R; Ogilvie AD; Sahakian J; Robbins TW Psychopharmacology (Berl); 2001 Dec; 159(1):10-20. PubMed ID: 11797064 [TBL] [Abstract][Full Text] [Related]
4. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Gibbs SE; D'Esposito M Psychopharmacology (Berl); 2005 Aug; 180(4):644-53. PubMed ID: 16001111 [TBL] [Abstract][Full Text] [Related]
5. Opposing roles for dopamine and serotonin in the modulation of human spatial working memory functions. Luciana M; Collins PF; Depue RA Cereb Cortex; 1998; 8(3):218-26. PubMed ID: 9617916 [TBL] [Abstract][Full Text] [Related]
6. Attenuation of working memory and spatial acquisition deficits after a delayed and chronic bromocriptine treatment regimen in rats subjected to traumatic brain injury by controlled cortical impact. Kline AE; Massucci JL; Marion DW; Dixon CE J Neurotrauma; 2002 Apr; 19(4):415-25. PubMed ID: 11990348 [TBL] [Abstract][Full Text] [Related]
7. DRD2 genotype predicts prefrontal activity during working memory after stimulation of D2 receptors with bromocriptine. Gelao B; Fazio L; Selvaggi P; Di Giorgio A; Taurisano P; Quarto T; Romano R; Porcelli A; Mancini M; Masellis R; Ursini G; De Simeis G; Caforio G; Ferranti L; Lo Bianco L; Rampino A; Todarello O; Popolizio T; Blasi G; Bertolino A Psychopharmacology (Berl); 2014 Jun; 231(11):2361-70. PubMed ID: 24424781 [TBL] [Abstract][Full Text] [Related]
8. Cortical effects of bromocriptine, a D-2 dopamine receptor agonist, in human subjects, revealed by fMRI. Kimberg DY; Aguirre GK; Lease J; D'Esposito M Hum Brain Mapp; 2001 Apr; 12(4):246-57. PubMed ID: 11241875 [TBL] [Abstract][Full Text] [Related]
9. Differential effect of a dopaminergic agonist on prefrontal function in traumatic brain injury patients. McDowell S; Whyte J; D'Esposito M Brain; 1998 Jun; 121 ( Pt 6)():1155-64. PubMed ID: 9648550 [TBL] [Abstract][Full Text] [Related]
10. Effects of tolcapone and bromocriptine on cognitive stability and flexibility. Cameron IGM; Wallace DL; Al-Zughoul A; Kayser AS; D'Esposito M Psychopharmacology (Berl); 2018 Apr; 235(4):1295-1305. PubMed ID: 29427081 [TBL] [Abstract][Full Text] [Related]
11. Dopaminergic modulation of distracter-resistance and prefrontal delay period signal. Bloemendaal M; van Schouwenburg MR; Miyakawa A; Aarts E; D'Esposito M; Cools R Psychopharmacology (Berl); 2015 Mar; 232(6):1061-70. PubMed ID: 25300902 [TBL] [Abstract][Full Text] [Related]
12. Cognitive effects of the dopamine receptor agonist pergolide. Kimberg DY; D'Esposito M Neuropsychologia; 2003; 41(8):1020-7. PubMed ID: 12667537 [TBL] [Abstract][Full Text] [Related]
14. Comparative effects of the dopaminergic agonists piribedil and bromocriptine in three different memory paradigms in rodents. Marighetto A; Valerio S; Philippin JN; Bertaina-Anglade V; Drieu la Rochelle C; Jaffard R; Morain P J Psychopharmacol; 2008 Jul; 22(5):511-21. PubMed ID: 18308794 [TBL] [Abstract][Full Text] [Related]
15. The modulatory effects of dopamine D1 and D2 receptor function on object working memory in humans. Bartholomeusz CF; Box G; Van Rooy C; Nathan PJ J Psychopharmacol; 2003 Mar; 17(1):9-15. PubMed ID: 12680735 [TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists disrupt visual latent inhibition in normal males using a within-subject paradigm. Swerdlow NR; Stephany N; Wasserman LC; Talledo J; Sharp R; Auerbach PP Psychopharmacology (Berl); 2003 Sep; 169(3-4):314-20. PubMed ID: 12610717 [TBL] [Abstract][Full Text] [Related]
17. Effects of dopaminergic modulation on electrophysiological brain response to affective stimuli. Franken IH; Nijs I; Pepplinkhuizen L Psychopharmacology (Berl); 2008 Jan; 195(4):537-46. PubMed ID: 17891382 [TBL] [Abstract][Full Text] [Related]
18. A functional magnetic resonance imaging study of the effects of pergolide, a dopamine receptor agonist, on component processes of working memory. Gibbs SE; D'Esposito M Neuroscience; 2006 Apr; 139(1):359-71. PubMed ID: 16458442 [TBL] [Abstract][Full Text] [Related]
19. Noradrenaline transporter blockade increases fronto-parietal functional connectivity relevant for working memory. Hernaus D; Casales Santa MM; Offermann JS; Van Amelsvoort T Eur Neuropsychopharmacol; 2017 Apr; 27(4):399-410. PubMed ID: 28291572 [TBL] [Abstract][Full Text] [Related]
20. Cholinergic, But Not Dopaminergic or Noradrenergic, Enhancement Sharpens Visual Spatial Perception in Humans. Gratton C; Yousef S; Aarts E; Wallace DL; D'Esposito M; Silver MA J Neurosci; 2017 Apr; 37(16):4405-4415. PubMed ID: 28336568 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]